title: Missing Value Estimation for Compound-Target Activity Data.
abstract: Relationships between drug targets and associated diseases have traditionally been investigated by means of sequence similarity, comparative protein modeling, and pathway analysis. Recently, a complementary paradigm has emerged to link targets and drugs via biological responses within activity data and visualize findings in networks. It has been indicated that one of the obstacles towards the identification of novel interactions is the sparsity of available data. In this article, we provide a survey of estimation methods that address the challenge of data sparsity. Each method is described in terms of its advantages and limitations, and an exemplary application on compound-target activity data is demonstrated. With such imputation methods in-hand, the opportunity to combine efforts in molecular informatics can be realized, yielding novel insights into ligand-target space.
authors.affiliation: Pharma Research & Early Development Informatics, Hoffmann-La Roche Inc. 340 Kingsland Street, Nutley, NJ 07110, USA phone/fax: +1-973-235-6834/-8531. yusuf.tanrikulu@roche.com.
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Tanrikulu
authors.affiliation: Discovery Chemistry, Hoffmann-La Roche Inc. 340 Kingsland Street, Nutley, NJ 07110, USA.
authors.forename: Rama
authors.initials: R
authors.lastname: Kondru
authors.affiliation: ETH Zürich, Computer-Assisted Drug Design, Wolfgang-Pauli Str. 10, 8093 Zürich, Switzerland.
authors.forename: Gisbert
authors.initials: G
authors.lastname: Schneider
authors.affiliation: Pharma Research & Early Development Informatics, Hoffmann-La Roche Inc. 340 Kingsland Street, Nutley, NJ 07110, USA phone/fax: +1-973-235-6834/-8531.
authors.forename: W Venus
authors.initials: WV
authors.lastname: So
authors.affiliation: Translational Research Sciences, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110, USA.
authors.forename: Hans-Marcus
authors.initials: HM
authors.lastname: Bitter
keywords: Data imputation; Drug design; Drug profiling; Poly-pharmacology; Target networks